

Resource Summary Report

Generated by [dkNET](#) on Aug 6, 2026

Purified anti-mouse/human CD44

RRID:AB_312953

Type: Antibody

Proper Citation

BioLegend Cat# 103002, RRID:AB_312953

Antibody Information

URL: http://antibodyregistry.org/AB_312953

Proper Citation: BioLegend Cat# 103002, RRID:AB_312953

Target Antigen: CD44

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC, IHC-F, CyTOF®, ELISA, ICC, IHC-P, IP, CMCD, Stim

Antibody Name: Purified anti-mouse/human CD44

Description: This monoclonal targets CD44

Target Organism: mouse, human

Clone ID: Clone IM7

Antibody ID: AB_312953

Vendor: BioLegend

Catalog Number: 103002

Alternative Catalog Numbers: 103001

Record Creation Time: 20250820T025936+0000

Record Last Update: 20250820T150354+0000

Ratings and Alerts

No rating or validation information has been found for Purified anti-mouse/human CD44.

No alerts have been found for Purified anti-mouse/human CD44.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 17 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Cheng JN, et al. (2025) Bone metastases diminish extraosseous response to checkpoint blockade immunotherapy through osteopontin-producing osteoclasts. *Cancer cell*, 43(6), 1093.

Shi T, et al. (2025) CHI3L3+ immature neutrophils inhibit anti-tumor immunity and impede immune checkpoint blockade therapy in bone metastases. *Cancer cell*.

Barlow GL, et al. (2025) The extra-islet pancreas supports autoimmunity in human type 1 diabetes. *eLife*, 13.

Stankiewicz LN, et al. (2025) Sex-biased human thymic architecture guides T cell development through spatially defined niches. *Developmental cell*, 60(1), 152.

Hirai H, et al. (2025) Co-colonization and Co-culture of Lung Alveoli Epithelial Stem Cells and Their Endothelial Niche Cells. *Methods in molecular biology (Clifton, N.J.)*, 2939, 169.

Gray GK, et al. (2023) Single-cell and spatial analyses reveal a tradeoff between murine mammary proliferation and lineage programs associated with endocrine cues. *Cell reports*, 42(10), 113293.

Jovanovi? B, et al. (2023) Heterogeneity and transcriptional drivers of triple-negative breast cancer. *Cell reports*, 42(12), 113564.

Yu S, et al. (2023) Systemic immune profiling of Omicron-infected subjects inoculated with different doses of inactivated virus vaccine. *Cell*, 186(21), 4615.

Canella A, et al. (2023) Genetically modified IL2 bone-marrow-derived myeloid cells reprogram the glioma immunosuppressive tumor microenvironment. *Cell reports*, 42(8), 112891.

Lee JH, et al. (2022) Characterization of adipose depot-specific stromal cell populations by single-cell mass cytometry. *iScience*, 25(4), 104166.

Hailemichael Y, et al. (2022) Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. *Cancer cell*, 40(5), 509.

Lu Y, et al. (2018) Th9 Cells Represent a Unique Subset of CD4+ T Cells Endowed with the Ability to Eradicate Advanced Tumors. *Cancer cell*, 33(6), 1048.

An Y, et al. (2018) Cdh1 and Pik3ca Mutations Cooperate to Induce Immune-Related Invasive Lobular Carcinoma of the Breast. *Cell reports*, 25(3), 702.

Gubin MM, et al. (2018) High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy. *Cell*, 175(4), 1014.

Snell LM, et al. (2018) CD8+ T Cell Priming in Established Chronic Viral Infection Preferentially Directs Differentiation of Memory-like Cells for Sustained Immunity. *Immunity*, 49(4), 678.

Evrard M, et al. (2018) Developmental Analysis of Bone Marrow Neutrophils Reveals Populations Specialized in Expansion, Trafficking, and Effector Functions. *Immunity*, 48(2), 364.

Hinohara K, et al. (2018) KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance. *Cancer cell*, 34(6), 939.